Genius ENGAGETM, a mobile application developed by Exom Group, has been selected as a finalist for the Scrip Awards 2017 in the category of Best Technological Development in Clinical Trials – Patient-focused. Genius ENGAGETM is the industry's first electronic Informed Consent solution that digitally integrates with the electronic trial master file and electronic case report form. It allows for an interactive and multi-media Informed Consent process on a tablet that is compliant with legal and regulatory requirements. Being selected as a finalist represents Exom Group's achievement in introducing disruptive mobile digital solutions to clinical trials.

1. Genius ENGAGE™, the eIC by Exom Group, has been selected
among the finalists of the Scrip Awards 2017
London, 14 September 2017
We are delighted to announce that our mobile application Genius ENGAGE™, has been selected as a
finalist of the Scrip Awards 2017 , for the category : Best Technological Development in Clinical Trials –
Patient-focused.
Genius ENGAGE™, the industry’s first ever electronic Informed Consent solution whose digital
workflow is fully combined with the eTMF, and integrated with the eCRF, admitting data entry only
after the patient has digitally signed the consent form.
Genius ENGAGE™ allows for a multi-media and interactive Informed Consent process on a flexible
computer tablet based platform, which is compliant with all legal and regulatory requirements.
“To be among the four finalists of the Scrip Awards 2017 for the category -Best Technological
Development in Clinical Trials- Patient focused – represents a great achievement of our company
proving the value of our mission in introducing disruptive mobile digital solutions in in clinical trials”
-said Luigi Visani MD, President & CEO of Exom Group -
“This new process of obtaining the patient’s consent to participate to a clinical trial has clear
advantages over the conventional way. Now we have a multi-languages and multi media-based
informed consent process with real-time tracking options, which provide more consistent and better
understanding to study subjects. Ultimately Genius ENGAGE™ will enable remote study models, such
as patient-centric or site-less clinical trials and potentially set new quality standards “